心脉医疗收盘下跌2.73%，滚动市盈率25.36倍，总市值113.48亿元

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Xinmai Medical, indicating a decline in revenue and profit in the latest quarterly report, alongside a relatively low PE ratio compared to the industry average [1][2][3] Group 2 - Xinmai Medical's main business focuses on the research, production, and sales of interventional medical devices for aortic and peripheral blood vessels, with key products including stent systems and balloon catheters [2] - The company reported a revenue of 332 million yuan for Q1 2025, a year-on-year decrease of 7.23%, and a net profit of 130 million yuan, down 29.66% year-on-year, with a gross profit margin of 69.61% [2] - As of Q1 2025, 11 institutions held shares in Xinmai Medical, with a total of 56.58 million shares valued at approximately 5.098 billion yuan [1] - The company's current PE ratio stands at 25.36, significantly lower than the industry average of 51.42 and the median of 37.44, ranking it 56th in the industry [1][3]